Faculdade de Medicina de Botucatu Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2000
NCT00626977
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Botucatu Medical School | Botucatu Medical School - UNESP | Faculdade de Medicina de Botucatu, Unesp | Faculdade de Medicina de Botucatu - UNESP | Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil

Active Ingredients

Drugs in Phase 4 Trials (1)

bacille calmette-guerin (1 trial)

Drugs in Phase 3 Trials (2)

vitamin c (1 trial)

vitamin e (1 trial)

Drugs in Other Trials (5)

clonidine (catapres) (1 trial)

erythromycin (ilosone) (1 trial)

guar gum (1 trial)

neomycin (1 trial)

ropivacaine (naropin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Eclampsia (Phase 3)

HELLP Syndrome (Phase 3)

Pre-Eclampsia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 8